Lung cancer trials in France

In France 316 Also abroad 2746

316 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
Where
Aix-en-Provence, Angers, Aurillac, Auxerre, Avignon, Bezannes, Béziers, Blois, Bordeaux, Bourg-en-Bresse, Caen, Carcassonne, Chalon Sur Sa Ne, Chambéry, Châteauroux, Créteil, Dieppe, Dinan, Dreux, Epagny METZ Tessy, Fort de France Cedex, Le Coudray, Limoges, Lyon, Marseille, Meaux, Metz, Mulhouse, Nancy, Nantes, Neuilly-sur-Seine, Nice, N MES, Perpignan, Reims, Rouen, Saint-Brieuc, Saint-Etienne, Saint-Herblain, Saint-Priest-en-Jarez, Strasbourg, Suresnes, Toulouse, Troyes, Valenciennes, Vandœuvre-lès-Nancy, Vannes, Villefranche-sur-Saône, Villeurbanne
Age
18 years and over
People
300 worldwide
Run by
AstraZeneca
See details and how to joinNCT06726720
Phase 3Active, not recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Where
Marseille, Paris, Saint-Herblain Cedex, Strasbourg Cedex
Age
18 years and over
People
582 worldwide
Run by
AstraZeneca
See details and how to joinNCT06350097 · EU 2023-509883-89-00
Phase 1/2Taking people
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Where
Créteil, Marseille, Paris Cedex 13, Suresnes, Toulouse
Age
18 years and over
People
594 worldwide
Run by
BioNTech SE
See details and how to joinNCT06892548 · EU 2024-520238-31-01
Phase 1Taking people
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Where
Bron, Marseille, Villejuif
Age
18 years to 99 years
People
160 worldwide
Run by
Amgen
See details and how to joinNCT07531095 · EU 2025-522888-15-00
Phase 3Taking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Bron, Caen Cedex 5, Lyon, Lyon Cedex 04, Marseille, Pierre-Bénite, Saint-Herblain, Saint-Herblain Cedex, Toulouse
Age
18 years and over
People
36 worldwide
Run by
Arrivent Biopharma Inc.
See details and how to join2025-522151-26-00
Phase 2Taking people
Phase 2, Multicenter, Open label, Platform Study investigating Tarlatamab (AMG 757) in patients with Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), with biomarker analysis to characterize response/resistance (UNLOCK TARLATAMAB)
Where
Bordeaux, Nice Cedex 2, Villejuif
Age
18 years and over
People
41 worldwide
Run by
Institut Gustave Roussy
See details and how to join2024-515847-47-00
Phase 1Not yet taking people in France
Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
Where
Pessac
People
7 worldwide
Run by
USWM Ct LLC
See details and how to join2024-513033-21-00
Phase 1Taking people
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours
Where
Bordeaux, Lille Cedex, Lyon Cedex 08, Marseille, Nice Cedex 2, Rennes, Villejuif
Age
18 years and over
People
138 worldwide
Run by
Deuteroncology
See details and how to join2023-504897-39-00
Phase 3Active, not recruiting
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
Where
Creteil Cedex, Lyon, Marseille, Paris, Rouen Cedex, Saint-Herblain, Toulon Cedex 9, Toulouse
Age
18 years and over
People
156 worldwide
Run by
Amgen Inc.
See details and how to join2024-520050-38-00
Phase 2Not yet taking people in France
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer
Where
Angers, Avignon, Bordeaux Cedex, Boulogne-Billancourt, Brest, Bron, Caen Cedex 9, Chambéry, Clermont Ferrand Cedex 1, Colmar Cedex, Grenoble Cedex 9, La Roche Sur Yon Cedex 9, Le Mans Cedex 9, Lille, Limoges Cedex 1, Marseille, Montpellier Cedex 5, Morlaix, Paris, Paris Cedex 13, Pessac Cedex, Poitiers, Reims, Saint-Herblain Cedex, Toulon Cedex 9, Tours, Vannes, Villefranche-sur-Saône
Age
18 years and over
People
177
Run by
Intergroupe Francophone de Cancerologie Thoracique
See details and how to joinNCT07759492 · EU 2025-522801-39-00
Phase 1/2Taking people
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Where
Villejuif
Age
18 years and over
People
366 worldwide
Run by
Marengo Therapeutics, Inc.
See details and how to joinNCT05592626 · EU 2023-505334-10-01
Phase 1/2Taking people
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Where
Clermont Ferrand Cedex1, Dijon, La Tronche, Lyon, Marseille, Nantes, Pessac, Toulouse Cedex 9, Vandoeuvre Les Nancy
Age
18 years and over
People
270 worldwide
Run by
Lumara Bio Oncologics GmbH
See details and how to joinNCT05706129 · EU 2023-504254-35-00
Phase 2Taking people
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
Where
Angers, ANGERS, Avignon Cedex 9, Boulogne-Billancourt, Brest, Bron Cedex, Caen Cedex 5, Caen Cedex 9, Chambéry, Créteil, Dijon, LE HAVRE, Le Mans Cedex 2, Le Mans Cedex 9, Lille, Lyon Cedex 04, Marseille, Metz, Montivilliers, Mulhouse, Orléans, Paris, Paris Cedex 18, Paris Cedex 20, Pessac Cedex, Pierre-Bénite, Rennes, Rennes Cedex, Rouen, Rouen Cedex, Saint-Cloud, Saint-Herblain, Strasbourg, Suresnes, Thionville, Toulouse, TOULOUSE Cedex, Tours, Valence, Valenciennes, Vandouvre Les Nancy, Vantoux, Villejuif
Age
18 years and over
People
152
Run by
Intergroupe Francophone de Cancerologie Thoracique
See details and how to joinNCT06656598 · EU 2024-517316-29-00
Phase 2Taking people
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
Where
Angers, Besancon Cedex, Bobigny Cedex, Boulogne-Billancourt, Boulogne-sur-Mer, Brest, Bron, Caen Cedex 9, Clermont Ferrand Cedex 1, Colmar Cedex, Créteil, Dijon, Epagny Metz-tessy, Grenoble Cedex 9, Lille, Marseille, Montpellier Cedex 5, Paris, Paris Cedex 13, Paris Cedex 18, Pessac, Rennes, Saint-Herblain, Strasbourg Cedex, Suresnes, Tours, Vantoux, Villefranche-sur-Saône
Age
18 years and over
People
108
Run by
Intergroupe Francophone de Cancerologie Thoracique
See details and how to joinNCT07420439 · EU 2025-522790-10-00
Phase 3Taking people
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Where
Avignon, Bordeaux, Créteil, Lille Cedex, Limoges, Lyon, Marseille, Montpellier, Montpellier Cedex 5, Mulhouse, Paris, Paris Cedex 20, Rennes, Saint-Herblain, Saint-Priest-en-Jarez, Suresnes, Villejuif
Age
18 years and over
People
540 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00
Phase 2Taking people
Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
Where
Bordeaux, Dijon, Marseille, Paris, Saint-Herblain, Vandœuvre-lès-Nancy, Villejuif
Age
18 years and over
People
60
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07483983
Phase 1Taking people
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Where
Bordeaux, Villejuif
Age
18 years and over
People
307 worldwide
Run by
Xencor, Inc.
See details and how to joinNCT05433142 · EU 2024-513619-28-00
Phase 1Taking people
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Where
Lyon, Villejuif
Age
18 years and over
People
434 worldwide
Run by
Amgen
See details and how to joinNCT07094113
Phase 1Taking people
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Where
Bron, Villejuif
Age
18 years to 100 years
People
162 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06562192
Phase 2Completed
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Créteil, Marseille, Paris, Strasbourg Cedex, Villejuif
Age
18 years and over
People
204 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Bordeaux, Paris, Villejuif
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 1Taking people
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Where
Villejuif
Age
18 years and over
People
914 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT06131840 · EU 2023-505858-18-00
Phase 1Taking people
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Where
Lyon, Toulouse, Villejuif
Age
18 years and over
People
710 worldwide
Run by
Incyte Corporation
See details and how to joinNCT06179160 · EU 2023-507091-47-00
Phase 1Not yet taking people in France
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Where
Bordeaux, Lyon, Villejuif Cedex
Age
18 years and over
People
240 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06476808 · EU 2025-523067-38-01
Phase 3Withdrawn
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
Where
Angers, Bordeaux, Créteil, Grenoble Cedex 9, Lyon, Montpellier, Pessac, Rouen Cedex, Saint-Herblain Cedex, Tours Cedex 9, Villejuif
Age
18 years and over
People
147 worldwide
Run by
Shanghai Junshi Biosciences Co. Ltd.
See details and how to join2023-507097-41-01